Canaccord analyst Whitney Ijem raised the firm’s price target on Intellia Therapeutics (NTLA) to $58 from $48 and keeps a Buy rating on the shares. The firm updated its model following positive Phase 3 topline data readout for lonvo-z in HAE. The efficacy data presented were straightforward and safety profile uneventful. As such, they don’t see regulatory risk to be an issue going forward.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs
- Intellia Therapeutics price target raised to $30 from $28 at Citizens
- Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)
- Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today
- Intellia Therapeutics announces $150M common stock offering